Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Applied Materials -- Ignore unavailable to you. Want to Upgrade?

To: Sam Citron who wrote (62524)	3/29/2002 7:39:37 PM
From: kdavy	Read Replies (2) \| Respond to of 70976

Sam: I can answer that for you. Go to FDA site, www.FDA.gov, go to CDER for Chemical entities (small molecules) or CBER for biologicals (recombinant proteins, vaccines, blood products etc.) You can get last 6 or 7 years of drugs approved. The answer to the second part is "No". There is no way of knowing in advance if letter will be approvable or not. For the "NDA" new drug application (final approval) there are two steps; first a review panel makes its recommendation and then some time later the the review committee meets and make a final decision. In most cases the committee follows the panel recommendations but there have been cases where the committee has turned down the panel recommendations. The success rate at the NDA level is pretty good roughly 40 to 50%( guessing). Most of the drug candidates drop out in the preclinical stage, or in Phase I, II or III stages. Check out the drugs in pipeline. If there are many then chances are that at least some of them will make it. Good luck. kdavy PS: only thing I am holding is 1000 shares of amat with cover calls strike price 50 and sold puts strike price at 45